Previous 10 | Next 10 |
Image source: The Motley Fool. IVERIC bio, Inc. (NASDAQ: ISEE) Q2 2022 Earnings Call Jul 26, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: IVERIC bio, Inc. (ISEE) Q2 2022 Earnings Call Transcript
IVERIC bio press release ( NASDAQ: ISEE ): Q2 GAAP EPS of -$0.41 misses by $0.09 . As of June 30, 2022, the Company had $312 million in cash, cash equivalents and available for sale securities. Shares +5.29% PM. For further details see: IVERIC bio GAA...
- Zimura ® GATHER2 Topline Data Expected in September of this Year- - GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% – - Agreement for up to $250 Million in Non-dilutive Debt Financing Secured...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing. ...
IVERIC bio ( NASDAQ: ISEE ) is scheduled to announce Q2 earnings results on Monday, July 25th, after market close. The consensus EPS estimate is -$0.30 . Over the last 3 months, EPS estimates have seen 3 upward revisions and 1 downward revision. For further d...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to...
After winning FDA’s priority review for its lead candidate pegcetacoplan in geographic atrophy (GA) secondary to age-related macular degeneration (AMD), the commercial-stage biotech Apellis Pharmaceuticals ( APLS ) has rallied its rivals targeting the eye disease. Not...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that in a post-hoc analysis from the GATHER1 clinical trial, Zimura showed a reduction of geographic atrophy lesion growth, compared to sham, across all distances from the foveal center point. The analysis was presented by David R. Lal...
Iveric Bio ( NASDAQ: ISEE ) garnered gains until noon trading today after Morgan Stanley raised its price target on the stock to $30 from $25 amidst favorable risk/reward ahead of Phase 3 GATHER2 Data in Q3 of 2022. Iveric said it expects data from a second phase 3 trial, ...
Iveric bio ( NASDAQ: ISEE ) signed a license agreement for the right to develop and commercialize new formulations of eye disorder drug candidate Zimura using DelSiTech's silica-based sustained release technology. Under the agreement, Iveric will pay DelSiTech ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...